| Drugs by Condition |  |
Angioedema Medications
Definition of Angioedema: Angioedema is the development of large welts below the surface of the skin, especially around the eyes and lips. The welts may also affect the hands, feet, and throat. The condition can be associated with allergies and histamine release.
Drugs associated with Angioedema
The following drugs and medications are in some way related to, or used in the treatment of Angioedema.
This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Drug Name  ( View by: Brand | Generic )
|
Reviews | Ratings |
|---|---|---|
Danocrine (Pro, More...) generic name: danazol class: miscellaneous hormones | 0 Review(s) | Not rated - Be the first |
| Winstrol (More...)generic name: stanozolol class: androgens and anabolic steroids | 0 Review(s) | Not rated - Be the first |
Angioedema Medications in the Pipeline
Cinryze (C1 inhibitor)
- May 6, 2008
Lev Pharmaceuticals Announces Cinryze Complete Response Submission Accepted for Review by FDA - May 2, 2008
Lev Announces FDA Advisory Committee Unanimously Recommends Approval of Cinryze for Hereditary Angioedema - April 15, 2008
Lev Pharmaceuticals Announces Submission of Complete Response to FDA for Cinryze for Hereditary Angioedema - March 13, 2008
Lev Announces FDA's Blood Products Advisory Committee to Review Cinryze (C1 inhibitor) - January 31, 2008
Lev Pharmaceuticals Receives Complete Response Letter for Cinryze - October 30, 2007
Lev Pharmaceuticals Amends Cinryze BLA to Include Prophylactic Data - October 1, 2007
Lev's Cinryze BLA Accepted for Filing by FDA - July 31, 2007
Lev Pharmaceuticals Submits Biologics License Application for Cinryze
Icatibant
- June 23, 2008
Jerini to Submit Complete Response to the FDA for Icatibant in the Treatment of HAE - April 24, 2008
FDA Issues Not Approvable Letter for Icatibant in the Treatment of HAE - January 8, 2008
FDA Cancels Advisory Committee Meeting for Icatibant in the Treatment of HAE - Priority Review of Jerini's NDA Continues - December 21, 2007
Jerini Receives NDA Filing Acceptance and Priority Review from the FDA for Icatibant in the Treatment of HAE - October 31, 2007
Jerini Submits New Drug Application for Icatibant in the Treatment of HAE to the FDA and Requests Priority Review - October 8, 2007
Jerini Initiates FDA Submission Process of New Drug Application for Icatibant in the Treatment of HAE
Rhucin (recombinant human C1 esterase inhibitor)
- January 29, 2008
Pharming Provides Update on Rhucin
Berinert P (C1-esterase inhibitor)
DX-88 (ecallantide)
Learn more about Angioedema
Medical encyclopedia results for:
